Over two decades helping clients navigate the difficult path of regulatory compliance.

mms holdings building

In 2006, MMS was created by Dr. Uma Sharma, with a vision to turn a one-person consultancy into a global, data-focused CRO that caters to the unique and often changing needs of sponsors. More than 20 years later, with an industry-leading customer satisfaction rating, MMS stays true to its dependable and customer-driven nature. A science-first approach and strong processes have smoothed the waters for MMS clients resulting in growth year over year, with more than 1,000 colleagues worldwide. 

MMS is a place where years of proven success have guided sponsors through their data strategy and regulatory submissions goals. When MMS takes on a project, colleagues become ingrained in that sponsor, taking on a greater level of care and guiding them towards a positive outcome. 

Sponsors that demand high quality come to MMS for strong industry expertise, a scientific approach to drug development, and top talent. Sponsors stay with MMS for its flexibility, agility, and a “do what it takes” attitude that is unrivaled in the industry. 

With a global footprint spanning four continents, MMS continues to earn industry recognition for excellence and innovation. The company has been honored with multiple awards including Best CRO – Specialist Provider at the Scrip Awards, Best Data-Focused CRO at the GHP Global Excellence Awards, Excellence in Client Service and Partnership at the Fierce CRO Awards, and Data Science Solution of the Year at the Data Breakthrough Awards for its Datacise® platform. 

In addition to these wins, MMS has been named a finalist and shortlisted across multiple industry recognition programs, including Citeline, ACDM, TOPRA, and Fierce Innovation, reflecting the breadth of its scientific and technological leadership. 

In 2025, MMS expanded its advanced analytics and trial design capabilities through the strategic acquisition of Exploristics, strengthening its leadership in simulation-driven development and trial design. This milestone reflected MMS’s continued investment in innovation and its commitment to helping sponsors make more confident development decisions. 

Recently, MMS has led breakthrough sponsor programs that include the following:  

  • TOGETHER Trial, which uses an Electronic Data Capture (EDC) system designed, built, and maintained by MMS, won the Society for Clinical Trial’s annual Trial of the Year Award.
  • Friends of Cancer Research, a leading nonprofit dedicated to accelerating innovation in cancer research, selected MMS to support the development of practical decision frameworks to inform the interpretation of interim overall survival (OS) data in oncology clinical trials.
  • Gates Ventures, in collaboration with Johnson & Johnson, AD Data Initiative, and the Global Neurodegeneration Proteomics Consortium (GNPC), chose MMS to support data intake, harmonization, and anonymization that united 250 million unique protein measurements from 35,000 biosamples across more than 20 international cohorts spanning Alzheimer’s Disease, Parkinson’s Disease, ALS, and Frontotemporal Dementia.

Behind every milestone and client partnership is a culture designed to empower exceptional talent, which has been recognized through multiple workplace awards. MMS has been certified as a Top Workplace in the United States and Michigan for multiple consecutive years as well as a Certified Great Place to Work in India and other global regions. 

To deliver high-quality service and technology solutions – rooted in strong science and decades of regulatory experience – that will assist our clients in developing and marketing life-changing therapies to positively improve lives worldwide.

Our Values

Strive for Good Science and Strong Processes

MMS is committed to making sound decisions based on strong scientific principles, internal expertise, and applicable regulation. As an organization, MMS emphasizes and values strong internal processes through defining, following, and improving upon the steps that lead to high-quality deliverables.

Value Talent – Find, Attract, Enhance and Retain

MMS recognizes that a talented staff is what drives our business forward. Identifying and attracting top talent and continual training to strengthen core skills are essential to core mission. At MMS, enthusiasm, collaboration, and teamwork is fostered, knowing that a global and diverse talent pool makes the company stronger.

Wow the Customer

MMS believes in delivering value beyond the competition. Each sponsor and researcher that MMS partners with is important and their goals relevant. MMS will strive to exceed their expectations by maintaining a customer focus throughout the project lifecycle, ensuring the customer experience is positive, building trust and forging long-term relationships.

Bring a Sense of Urgency and Leadership (SOUL)

MMS promotes the importance of SOUL through a healthy work environment and as a requirement for providing added value to clients. The SOUL of MMS comes to life as project work is completed on time and as risks and solutions are identified proactively. At MMS, each colleague takes responsibility for the success of every project.

Suggested For You

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 16th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today 

perspectives

January 20th, 2026

Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration 

perspectives

January 13th, 2026

Making Clinical Trial Technology Work in Practice